You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

LOTRIMIN ULTRA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Lotrimin Ultra patents expire, and what generic alternatives are available?

Lotrimin Ultra is a drug marketed by Bayer Healthcare Llc and is included in one NDA.

The generic ingredient in LOTRIMIN ULTRA is butenafine hydrochloride. There are two drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the butenafine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lotrimin Ultra

A generic version of LOTRIMIN ULTRA was approved as butenafine hydrochloride by TARO on November 16th, 2017.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LOTRIMIN ULTRA?
  • What are the global sales for LOTRIMIN ULTRA?
  • What is Average Wholesale Price for LOTRIMIN ULTRA?
Summary for LOTRIMIN ULTRA
US Patents:0
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 112
Clinical Trials: 4
What excipients (inactive ingredients) are in LOTRIMIN ULTRA?LOTRIMIN ULTRA excipients list
DailyMed Link:LOTRIMIN ULTRA at DailyMed
Drug patent expirations by year for LOTRIMIN ULTRA
Recent Clinical Trials for LOTRIMIN ULTRA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
BayerPhase 3
Taro Pharmaceuticals USAPhase 1

See all LOTRIMIN ULTRA clinical trials

Pharmacology for LOTRIMIN ULTRA

US Patents and Regulatory Information for LOTRIMIN ULTRA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare Llc LOTRIMIN ULTRA butenafine hydrochloride CREAM;TOPICAL 021307-001 Dec 7, 2001 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.